It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Neurofilament light chain (NfL), released during central nervous injury, has evolved as a powerful serum marker of disease severity in many neurological disorders, including infectious diseases. So far NfL has not been assessed in cerebral malaria in human or its rodent model experimental cerebral malaria (ECM), a disease that can lead to fatal brain edema or reversible brain edema. In this study we assessed if NfL serum levels can also grade disease severity in an ECM mouse model with reversible (n = 11) and irreversible edema (n = 10). Blood–brain-barrier disruption and brain volume were determined by magnetic resonance imaging. Neurofilament density volume as well as structural integrity were examined by electron microscopy in regions of most severe brain damage (olfactory bulb (OB), cortex and brainstem). NfL plasma levels in mice with irreversible edema (317.0 ± 45.01 pg/ml) or reversible edema (528.3 ± 125.4 pg/ml) were significantly increased compared to controls (103.4 ± 25.78 pg/ml) by three to five fold, but did not differ significantly in mice with reversible or irreversible edema. In both reversible and irreversible edema, the brain region most affected was the OB with highest level of blood–brain-barrier disruption and most pronounced decrease in neurofilament density volume, which correlated with NfL plasma levels (r = − 0.68, p = 0.045). In cortical and brainstem regions neurofilament density was only decreased in mice with irreversible edema and strongest in the brainstem. In reversible edema NfL plasma levels, MRI findings and neurofilament volume density normalized at 3 months’ follow-up. In conclusion, NfL plasma levels are elevated during ECM confirming brain damage. However, NfL plasma levels fail short on reliably indicating on the final outcomes in the acute disease stage that could be either fatal or reversible. Increased levels of plasma NfL during the acute disease stage are thus likely driven by the anatomical location of brain damage, the olfactory bulb, a region that serves as cerebral draining pathway into the nasal lymphatics.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Heidelberg University Hospital, Department of Neuroradiology, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); Heidelberg University Hospital, Centre for Infectious Diseases, Parasitology Unit, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
2 Heidelberg University Hospital, Centre for Infectious Diseases, Parasitology Unit, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
3 University of Lausanne, Electron Microscopy Facility, Faculty of Biology and Medicine, Lausanne, Switzerland (GRID:grid.9851.5) (ISNI:0000 0001 2165 4204)
4 Heidelberg University, Electron Microscopy Core Facility, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373)
5 University Hospital Basel, University of Basel, Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Basel, Switzerland (GRID:grid.410567.1)
6 Heidelberg University Hospital, Department of Neuroradiology, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
7 Heidelberg University Hospital, Centre for Infectious Diseases, Parasitology Unit, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); German Center for Infection Research (DZIF), Heidelberg, Germany (GRID:grid.452463.2)
8 Heidelberg University Hospital, Department of Neuroradiology, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); University Institute of Diagnostic and Interventional Neuroradiology, University Hospital Bern, Inselspital, University of Bern, Department of Neuroradiology, Bern, Switzerland (GRID:grid.411656.1) (ISNI:0000 0004 0479 0855)